Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
Alaunos Therapeutics announced new preclinical data for its metabolic candidate ALN1003, showing lower liver weight in diet-induced obese mice after adjustment for body fat percentage. The statistical analysis confirmed the findings with high significance (p=0.000005) and aligned with previous reductions in liver injury enzymes and HOMA-IR biomarkers.
Key figures
- Drug Name
- ALN1003
- P value hc3
- 0.000015
- Cash position
- $0.354 million
- P value anova
- 0.000005
- Nas score control
- 5
- Nas score treated
- 2.7
- Liver weight reduction
- 43%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.